These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 31619251

  • 1. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H.
    Health Qual Life Outcomes; 2019 Oct 16; 17(1):155. PubMed ID: 31619251
    [Abstract] [Full Text] [Related]

  • 2. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
    Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R.
    Am J Hematol; 2011 Mar 16; 86(3):273-7. PubMed ID: 21328441
    [Abstract] [Full Text] [Related]

  • 3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA, Barner JC.
    J Manag Care Spec Pharm; 2020 Nov 16; 26(11):1412-1422. PubMed ID: 33119448
    [Abstract] [Full Text] [Related]

  • 4. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A, Cong Z, Agodoa I, Song X, Martinez DJ, Black D, Lew CR, Varker H, Chan C, Lanzkron S.
    J Manag Care Spec Pharm; 2020 Sep 16; 26(9):1121-1129. PubMed ID: 32597290
    [Abstract] [Full Text] [Related]

  • 5. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
    Knight LMJ, Tanabe P, Blewer AL, Goodrich J, King AA, Reuter-Rice K, Crego N.
    Pediatr Blood Cancer; 2024 Jul 16; 71(7):e31017. PubMed ID: 38706206
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
    Stallworth JR, Jerrell JM, Tripathi A.
    Am J Hematol; 2010 Oct 16; 85(10):795-7. PubMed ID: 20645429
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
    Crego N, Douglas C, Bonnabeau E, Earls M, Eason K, Merwin E, Rains G, Tanabe P, Shah N.
    J Am Board Fam Med; 2020 Oct 16; 33(1):91-105. PubMed ID: 31907250
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S, Haywood C, Segal JB, Dover GJ.
    Am J Hematol; 2006 Dec 16; 81(12):927-32. PubMed ID: 16924648
    [Abstract] [Full Text] [Related]

  • 11. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE, Gladwin MT, Byrne M, Hildesheim M, Krishnamurti L.
    Pediatr Blood Cancer; 2014 Jun 16; 61(6):1068-73. PubMed ID: 24436121
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S, Chisolm D, Stanek J, Hankins J, O'Brien SH.
    JMIR Mhealth Uhealth; 2019 Aug 08; 7(8):e13452. PubMed ID: 31397291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.